Open AccessThe effect of remdesivir on selective biomarkers and its value in predicting the clinical outcome in patients with COVID-19
Author(s) -
Sanjana Rai,
Dyna Jones,
Chinnappa Anjanappa Jayashankar,
Venkata Bharat Kumar Pinnelli,
Eashwer Manpreeth,
Venkata Sai Raghava Prashanthi Seetha
Publication year - 2021
Publication title -
asian journal of medical sciences
Language(s) - English
Resource type - Journals
ISSN - 2091-0576
DOI - 10.3126/ajms.v12i12.39164
Subject(s) - medicine , lactate dehydrogenase , creatinine , mann–whitney u test , c reactive protein , ferritin , gastroenterology , retrospective cohort study , covid-19 , inflammation , disease , enzyme , biochemistry , chemistry , infectious disease (medical specialty)
Background: To the best of our knowledge, there have been no studies to evaluate the effect of remdesivir on inflammatory markers.Aims and Objectives: To study the effect of Remdesivir on Selective biomarkers namely C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH), Serum Ferritin and D-dimer and their value in predicting the clinical outcome in patients with COVID -19 infection.Materials and Methods: This is a retrospective observational study including 102 laboratory-confirmed COVID-19 patients of moderate and severe category who were subjected to complete blood count, liver function test, BUN, creatinine, C-reactive protein, lactate dehydrogenase, D-dimer, serum ferritin, ECG, and chest X-ray. The association was analyzed using independent sample t-test or Mann–Whitney U-test. Patients were divided into two groups. Both received corticosteroids and anticoagulants. Group A also received remdesivir.Results: Of the 102 patients, 90.2% of the patients in the non-remdesivir group and 94.1% in the remdesivir group were discharged. The mortality rate was 9.8% in the non-remdesivir group versus 5.9% in the remdesivir group (P=0.71). There was no statistically significant difference in the decrease of the inflammatory markers overtime in both the groups, irrespective of whether they received remdesivir or not.Conclusion: High values of the inflammatory markers were seen at the time of admission. A 5 days course of remdesivir failed to demonstrate a statistically significant difference in the decrease in the levels of the inflammatory markers. However, we have observed a possible clinical benefit of remdesivir among patients with moderate and severe COVID-19 disease, as there was a trend toward better clinical outcomes. Further studies are needed to evaluate this therapeutic strategy.